SignaCor is an innovative biotechnology company focused on transforming the treatment of cardiovascular disease. The company is pioneering a new approach to heart conditions by addressing the root biological drivers of disease rather than simply managing symptoms.
At its core, SignaCor is developing first-in-class therapeutics for hypertrophic cardiomyopathy (HCM), a genetic condition that causes the heart muscle to thicken and function less effectively. While existing treatments primarily focus on symptom relief, SignaCor’s approach is designed to modify and potentially reverse disease progression, offering a more meaningful and lasting clinical impact.
The company’s technology leverages epigenetic mechanisms, including DNA methylation, to target multiple pathways involved in cardiac dysfunction such as fibrosis. By addressing these underlying processes, SignaCor aims to deliver broader therapeutic benefits and improve long-term outcomes for patients.
With a strong scientific foundation and a clear focus on clinical translation, SignaCor is advancing its lead programmes while building a pipeline of therapies for wider cardiovascular conditions.
SignaCor’s mission is to redefine the future of heart disease treatment - developing breakthrough therapies that go beyond symptom management to fundamentally change how cardiovascular disease is treated.
Visit website